Peyronie's Disease
22
3
6
13
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
4.5%
1 terminated out of 22 trials
92.9%
+6.4% vs benchmark
36%
8 trials in Phase 3/4
54%
7 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (22)
Title Fractioned CO2 Laser in the Treatment of Chronic Phase Peyronie's Disease
Platelet-Rich Plasma for Peyronie's Disease
Treatment of Peyronie's Disease With Platelet-Rich Plasma
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis
Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's
Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders
Fractionated Carbon Dioxide Laser Therapy for Treatment of Peyronie's Disease
Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease
H-22411: BOTOX® for Peyronie's Disease
Intralesional Hyaluronic Acid and Verapamil Injection in Peyronie's Disease
Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease
An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease
Study of AA4500 in the Treatment of Peyronie's Disease
Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease
Study of AA4500 in the Treatment of Peyronie's Disease
A Study of AA4500 in Men With Peyronie's Disease
A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease
The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease